Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 14/20 | 0.43 |
| ▸ | PPARA | Q07869 | 12/20 | 0.43 |
| ▸ | PPARD | Q03181 | 3/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6818678 | 0.90 | PPARG (0.46) | PPARGPPARAPPARDSLC7A5ALOX5 | |
| SCHEMBL6834707 | 0.87 | PPARG (0.56) | PPARGPPARAPPARDSLC7A5 | |
| SCHEMBL979752 | 0.80 | SLC7A5 (0.56) | PPARGPPARAPPARDSLC7A5SMN1; SMN2 | |
| SCHEMBL977574 | 0.78 | SLC7A5 (0.54) | PPARGPPARAPPARDSLC7A5 | |
| SCHEMBL978773 | 0.77 | SLC7A5 (0.62) | PPARGPPARAPPARDSLC7A5 | |
| SCHEMBL3535238 | 0.77 | PPARA (0.39) | PPARGPPARAPPARDALOX5 | |
| SCHEMBL3535233 | 0.77 | PPARA (0.39) | PPARGPPARAPPARDALOX5 | |
| SCHEMBL3533612 | 0.76 | PPARA (0.50) | PPARGPPARAPPARD | |
| SCHEMBL3533617 | 0.76 | PPARA (0.50) | PPARGPPARAPPARD | |
| SCHEMBL6822848 | 0.76 | PPARG (0.56) | PPARGPPARAPPARDALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6750252-B2 | FOR USE IN CLINICAL CONDITIONS ASSOCIATED WITH INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2004-06-15 | — | — | US | disclosed |
| EP-1237856-B1 | NEW TRI-SUBSTITUTED PHENYL DERIVATIVES AND ANALOGUES | ASTRAZENECA AB (SE) | 2004-05-12 | — | — | EP | disclosed |
| US-20030149104-A1 | Tri-substituted phenyl derivatives and analogues | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | US | disclosed |
| EP-1237856-A1 | NEW TRI-SUBSTITUTED PHENYL DERIVATIVES AND ANALOGUES | AstraZeneca AB (SE) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001040172-A1 | NEW TRI-SUBSTITUTED PHENYL DERIVATIVES AND ANALOGUES | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149104-A1 | Tri-substituted phenyl derivatives and analogues | GPR119, IAPP, INSR | PPARG 46/4885PPARA 87/4885PPARD 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.